Physician profile
Michael Alan Mcgriff
NPI 1952337966
$1,741.38
in general payments reported to CMS, 2019-2025
12 companies · $305 in 2025
The $305 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $152 · 2021: $47.59 · 2022: $110 · 2023: $560 · 2024: $567 · 2025: $305.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,334 · Education: $98.35.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,333.84 |
| Education | $98.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $524.16 | 2022-2025 | Sotyktu |
| Abbvie INC. | $393.41 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $253.39 | 2024-2025 | Dupixent, Libtayo |
| Galderma Laboratories, L.P. | $136.54 | 2019-2023 | |
| Allergan, INC. | $105.94 | 2019 | |
| Genzyme Corporation | $70.56 | 2022-2023 | |
| Ucb, INC. | $53.17 | 2025 | Bimzelx |
| Boehringer Ingelheim Pharmaceuticals, INC. | $49.18 | 2023 | Spevigo |
| Hill Dermaceuticals, INC. | $48.72 | 2024 | Tolak |
| Novartis Pharmaceuticals Corporation | $47.42 | 2024 | |
| Organogenesis INC. | $30.23 | 2022 | |
| Amgen INC. | $28.66 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Mcgriff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.